Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease

Study Identifier
223575-002
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Dry Eye
  • Study Drug
  • AGN-223575 ophthalmic solution
  • AGN-223575 vehicle ophthalmic solution
  • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.

    Study Locations

    Location
    Status
    Location
    Arizona Center for Clinical Trials
    Phoenix, Arizona, United States, 85003
    Status
    Not applicable
    Location
    Specialty Eye Ctr. Med. Group
    Glendale, California, United States, 91203
    Status
    Not applicable
    Location
    The Eye Research Foundation
    Newport Beach, California, United States, 92663
    Status
    Not applicable
    Location
    WCCT Global
    Santa Ana, California, United States, 92705
    Status
    Not applicable
    Location
    Eye Associates of Colorado Springs
    Colorado Springs, Colorado, United States, 80909
    Status
    Not applicable
    Location
    West Coast Eye Institute
    Lecanto, Florida, United States, 34491
    Status
    Not applicable
    Showing {first} - {last} of {total} Results